Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ziessman, H. A.
Right arrow Articles by Tuscan, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ziessman, H. A.
Right arrow Articles by Tuscan, M. C.

Radiology, Vol 152, 167-172, Copyright © 1984 by Radiological Society of North America

ARTICLES

Hepatic arterial perfusion scintigraphy with Tc-99m-MAA. Use of a totally implanted drug delivery system

HA Ziessman, JH Thrall, PJ Yang, SC Walker, EA Cozzi, JE Niederhuber, JW Gyves, WD Ensminger and MC Tuscan

Tc-99m-MAA hepatic arterial perfusion scintigraphy ( HAPS ) using a totally implanted drug delivery system was employed for hepatic arterial chemotherapy in 147 patients (335 studies). Complete perfusion of the involved liver was seen in 88% of patients initially [more so in those with normal hepatic vascular anatomy (93%) than those with vascular variants (79%)] and remained good on follow-up. In 67 consecutive patients (95 studies), arteriovenous shunting to the lung ranged from 0.4 to 32% (mean, 6.2% +/- 4.1 S.D.). Uptake at the tip of the catheter was increased in 20% of patients, but good perfusion was usually maintained. A significant decrease in hepatic and/or extrahepatic perfusion associated with a "hot spot" at the tip of the catheter indicated hepatic arterial thrombosis. Extrahepatic perfusion was seen in 14% of cases, usually in the distribution of the stomach, small bowel, and spleen. Significant symptoms of drug toxicity were seen in 70% of patients with extrahepatic perfusion, compared to 19% of those without it.


This article has been cited by other articles:


Home page
 Am. J. Roentgenol.Home page
S. Murata, H. Tajima, Y. Abe, T. Fukunaga, K. Nakazawa, R. A. A. Mohamad, and T. Kumazaki
Temporary Occlusion of Two Hepatic Veins for Chemoembolization of Hepatocellular Carcinoma with Arteriohepatic Vein Shunts
Am. J. Roentgenol., February 1, 2005; 184(2): 415 - 417.
[Full Text] [PDF]

Home page
 JNMHome page
J. Taki, H. Sumiya, T. Higuchi, H. Tsuchiya, K. Takazawa, K. Tomita, and N. Tonami
Prediction of Myocutaneous Adverse Side Effect Due to Intra-Arterial Chemotherapy by Intra-Arterial 99mTc-Macroaggregated Albumin Administration in Patients with Bone and Soft-Tissue Tumors
J. Nucl. Med., November 1, 2002; 43(11): 1452 - 1456.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 1984 by the Radiological Society of North America.